Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Gains from Sales and Divestitures (2021 - 2025)

Historic Gains from Sales and Divestitures for Rani Therapeutics Holdings (RANI) over the last 5 years, with Q3 2025 value amounting to $273546.0.

  • Rani Therapeutics Holdings' Gains from Sales and Divestitures fell 1547.07% to $273546.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $273546.0, marking a year-over-year decrease of 1547.07%. This contributed to the annual value of $394760.0 for FY2024, which is 3317.23% down from last year.
  • According to the latest figures from Q3 2025, Rani Therapeutics Holdings' Gains from Sales and Divestitures is $273546.0, which was down 1547.07% from $215745.0 recorded in Q2 2025.
  • Rani Therapeutics Holdings' 5-year Gains from Sales and Divestitures high stood at $590713.0 for Q4 2023, and its period low was $15058.0 during Q3 2021.
  • Its 5-year average for Gains from Sales and Divestitures is $214116.6, with a median of $241697.5 in 2022.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first soared by 167746.05% in 2022, then plummeted by 3317.23% in 2024.
  • Over the past 5 years, Rani Therapeutics Holdings' Gains from Sales and Divestitures (Quarter) stood at $21800.0 in 2021, then soared by 1127.75% to $267650.0 in 2022, then surged by 120.7% to $590713.0 in 2023, then tumbled by 33.17% to $394760.0 in 2024, then crashed by 30.71% to $273546.0 in 2025.
  • Its last three reported values are $273546.0 in Q3 2025, $215745.0 for Q2 2025, and $156886.0 during Q1 2025.